Back

Population-based analysis of POT1 variants in a cutaneous melanoma case-control cohort

Simonin-Wilmer, I.; Ossio, R.; Leddin, E.; Harland, M.; Pooley, K. A.; Martil de la Garza, M. G.; Obolenski, S.; Hewinson, J.; Wong, C. C.; Iyer, V.; Taylor, J. C.; Newton-Bishop, J. A.; Bishop, D. T.; Cisneros, G. A.; Iles, M. M.; Adams, D. J.; Robles-Espinoza, C. D.

2022-05-19 genetic and genomic medicine
10.1101/2022.05.16.22274971 medRxiv
Show abstract

Pathogenic germline variants in the protection of telomeres 1 gene (POT1) have been associated with predisposition to a range of tumor types, including melanoma, glioma, leukemia and cardioangiosarcoma. We sequenced all coding exons of the POT1 gene in 2,929 European-descent melanoma cases and 3,298 controls, identifying 43 protein-changing genetic variants. We performed POT1-telomere binding assays for all missense and stop gained variants, finding nine variants that impair or disrupt protein-telomere complex formation, and we further define the role of variants in the regulation of telomere length and complex formation through molecular dynamics simulations. We determine that POT1 variants are a minor contributor to melanoma burden in the general population, with only about 0.5% of melanoma cases carrying germline pathogenic variants in this gene, but should be screened in individuals with a strong family history of melanoma and/or multiple malignancies.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.